BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med. 2020;34:223-231. [PMID: 32535732 DOI: 10.1007/s40290-020-00342-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 57] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 McMurray JC, May JW, Cunningham MW, Jones OY. Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment. Front Pediatr 2020;8:626182. [PMID: 33425823 DOI: 10.3389/fped.2020.626182] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
2 Dyavar SR, Singh R, Emani R, Pawar GP, Chaudhari VD, Podany AT, Avedissian SN, Fletcher CV, Salunke DB. Role of toll-like receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-CoV2 infection and potential therapeutic options. Biomed Pharmacother 2021;141:111794. [PMID: 34153851 DOI: 10.1016/j.biopha.2021.111794] [Reference Citation Analysis]
3 Hasan MJ, Rabbani R, Anam AM, Huq SMR. Additional baricitinib loading dose improves clinical outcome in COVID-19. Open Med (Wars) 2021;16:41-6. [PMID: 33364433 DOI: 10.1515/med-2021-0010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Elahi R, Karami P, Heidary AH, Esmaeilzadeh A. An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19). International Immunopharmacology 2022;105:108536. [DOI: 10.1016/j.intimp.2022.108536] [Reference Citation Analysis]
5 Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng M, Sundaram B, Banoth B, Malireddi RKS, Schreiner P, Neale G, Vogel P, Webby R, Jonsson CB, Kanneganti TD. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell 2021;184:149-168.e17. [PMID: 33278357 DOI: 10.1016/j.cell.2020.11.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 124] [Article Influence: 65.5] [Reference Citation Analysis]
6 Paraiso IL, Revel JS, Stevens JF. Potential use of polyphenols in the battle against COVID-19.Curr Opin Food Sci. 2020;32:149-155. [PMID: 32923374 DOI: 10.1016/j.cofs.2020.08.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
7 Baten N, Wajed S, Talukder A, Masum MHU, Rahman MM. Coinfection of fungi with SARS-CoV-2 is a detrimental health risk for COVID-19 patients. Beni-Suef Univ J Basic Appl Sci 2022;11. [DOI: 10.1186/s43088-022-00245-9] [Reference Citation Analysis]
8 Khan MA, Khan ZA, Charles M, Pratap P, Naeem A, Siddiqui Z, Naqvi N, Srivastava S. Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms. J Inflamm Res. 2021;14:175-189. [PMID: 33519225 DOI: 10.2147/jir.s271292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
9 Zhou T, Su TT, Mudianto T, Wang J. Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. J Exp Med 2020;217:e20200674. [PMID: 32910820 DOI: 10.1084/jem.20200674] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
10 Bahrami A, Arabestani MR, Taheri M, Farmany A, Zadeh FN, Hosseini SM, Nozari H, Nouri F. Exploring the Role of Heavy Metals and Their Derivatives on the Pathophysiology of COVID-19. Biol Trace Elem Res 2021. [PMID: 34448983 DOI: 10.1007/s12011-021-02893-x] [Reference Citation Analysis]
11 Angurana SK, Bansal A. Probiotics and Coronavirus disease 2019: think about the link. Br J Nutr 2020;:1-7. [PMID: 32921328 DOI: 10.1017/S000711452000361X] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Golota AS, Kamilova TA, Shneider OV, Vologzhanin DA, Sherbak SG. Pathogenesis of the initial stages of severe COVID-19. Journal of Clinical Practice 2021;12:83-102. [DOI: 10.17816/clinpract71351] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Atal S, Fatima Z, Balakrishnan S. Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour? BioDrugs 2020;34:705-11. [PMID: 33048300 DOI: 10.1007/s40259-020-00448-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Marino A, Munafò A, Augello E, Bellanca CM, Bonomo C, Ceccarelli M, Musso N, Cantarella G, Cacopardo B, Bernardini R. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infectious Disease Reports 2022;14:360-71. [DOI: 10.3390/idr14030040] [Reference Citation Analysis]
15 Mahler M, Meroni PL, Infantino M, Buhler KA, Fritzler MJ. Circulating Calprotectin as a Biomarker of COVID-19 Severity. Expert Rev Clin Immunol 2021;17:431-43. [PMID: 33750254 DOI: 10.1080/1744666X.2021.1905526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
17 Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, Perez-Reviriego AA. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. World J Clin Cases 2020; 8(21): 5250-5283 [PMID: 33269260 DOI: 10.12998/wjcc.v8.i21.5250] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
18 Gunathilake TMSU, Ching YC, Uyama H, Chuah CH. Nanotherapeutics for treating coronavirus diseases. J Drug Deliv Sci Technol 2021;64:102634. [PMID: 34127930 DOI: 10.1016/j.jddst.2021.102634] [Reference Citation Analysis]
19 Bagherzade M, Parham M, Zohali S, Molaei S, Vafaeimanesh J. Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19. Caspian J Intern Med 2020;11:572-6. [PMID: 33425279 DOI: 10.22088/cjim.11.0.572] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Batra N, De Souza C, Batra J, Raetz AG, Yu AM. The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). Int J Mol Sci 2020;21:E6412. [PMID: 32899231 DOI: 10.3390/ijms21176412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
21 Xu K, Wei Y, Giunta S, Zhou M, Xia S. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people? Exp Gerontol 2021;151:111423. [PMID: 34048906 DOI: 10.1016/j.exger.2021.111423] [Reference Citation Analysis]
22 Ravindra NG, Alfajaro MM, Gasque V, Huston NC, Wan H, Szigeti-Buck K, Yasumoto Y, Greaney AM, Habet V, Chow RD, Chen JS, Wei J, Filler RB, Wang B, Wang G, Niklason LE, Montgomery RR, Eisenbarth SC, Chen S, Williams A, Iwasaki A, Horvath TL, Foxman EF, Pierce RW, Pyle AM, van Dijk D, Wilen CB. Single-cell longitudinal analysis of SARS-CoV-2 infection in human airway epithelium identifies target cells, alterations in gene expression, and cell state changes. PLoS Biol 2021;19:e3001143. [PMID: 33730024 DOI: 10.1371/journal.pbio.3001143] [Cited by in Crossref: 16] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
23 Tong X, Zheng Y, Li Y, Xiong Y, Chen D. Soluble ligands as drug targets for treatment of inflammatory bowel disease. Pharmacol Ther 2021;226:107859. [PMID: 33895184 DOI: 10.1016/j.pharmthera.2021.107859] [Reference Citation Analysis]
24 Pannone G, Caponio VCA, De Stefano IS, Ramunno MA, Meccariello M, Agostinone A, Pedicillo MC, Troiano G, Zhurakivska K, Cassano T, Bizzoca ME, Papagerakis S, Buonaguro FM, Advani S, Muzio LL. Lung histopathological findings in COVID-19 disease - a systematic review. Infect Agent Cancer 2021;16:34. [PMID: 34001199 DOI: 10.1186/s13027-021-00369-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li S, Cheng CS, Zhang C, Tang GY, Tan HY, Chen HY, Wang N, Lai AY, Feng Y. Edible and Herbal Plants for the Prevention and Management of COVID-19. Front Pharmacol 2021;12:656103. [PMID: 33995078 DOI: 10.3389/fphar.2021.656103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Imperio GE, Lye P, Mughis H, Hamada H, Bloise E, Lye SJ, Matthews SG. Hypoxia alters the expression of ACE2 and TMPRSS2 SARS-CoV-2 cell entry mediators in hCMEC/D3 brain endothelial cells. Microvasc Res 2021;138:104232. [PMID: 34416267 DOI: 10.1016/j.mvr.2021.104232] [Reference Citation Analysis]
27 Sgherza N, Curci P, Strafella V, Rizzi R, Musto P. Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma. Acta Biomed 2021;92:e2021205. [PMID: 33988136 DOI: 10.23750/abm.v92i2.11395] [Reference Citation Analysis]
28 Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 2020;262:118510. [PMID: 32991879 DOI: 10.1016/j.lfs.2020.118510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
29 Barh D, Aljabali AA, Tambuwala MM, Tiwari S, Serrano-Aroca Á, Alzahrani KJ, Silva Andrade B, Azevedo V, Ganguly NK, Lundstrom K. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines 2021;9:556. [PMID: 34067609 DOI: 10.3390/biomedicines9050556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, Capela C, Pedrosa J, Castro AG, Silvestre R. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol 2021;12:613422. [PMID: 33679753 DOI: 10.3389/fimmu.2021.613422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
31 Yasmin F, Najeeb H, Moeed A, Hassan W, Khatri M, Asghar MS, Naveed AK, Ullah W, Surani S. Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials. PLoS One 2022;17:e0266245. [PMID: 35381033 DOI: 10.1371/journal.pone.0266245] [Reference Citation Analysis]
32 Kotak S, Khatri M, Malik M, Malik M, Hassan W, Amjad A, Malik F, Hassan H, Ahmed J, Zafar M. Use of Tocilizumab in COVID-19: A Systematic Review and Meta-Analysis of Current Evidence. Cureus 2020;12:e10869. [PMID: 33178522 DOI: 10.7759/cureus.10869] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
33 Španko M, Strnadová K, Pavlíček AJ, Szabo P, Kodet O, Valach J, Dvořánková B, Smetana K Jr, Lacina L. IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives. Int J Mol Sci 2021;22:11027. [PMID: 34681685 DOI: 10.3390/ijms222011027] [Reference Citation Analysis]
34 Caballero A, Filgueira LM, Betancourt J, Sánchez N, Hidalgo C, Ramírez A, Martinez A, Despaigne RE, Escalona A, Diaz H, Meriño E, Ortega LM, Castillo U, Ramos M, Saavedra D, García Y, Lorenzo G, Cepeda M, Arencibia M, Cabrera L, Domecq M, Estévez D, Valenzuela C, Lorenzo P, Sánchez L, Mazorra Z, León K, Crombet T. Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab. Clin Transl Immunology 2020;9:e1218. [PMID: 33304584 DOI: 10.1002/cti2.1218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020;3:205-212. [PMID: 33215063 DOI: 10.1093/abt/tbaa020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 13.5] [Reference Citation Analysis]
36 Sharma A, Shah M, Lakshmi S, Sane H, Captain J, Gokulchandran N, Khubchandani P, Pradeep MK, Gote P, Tuppekar B, Kulkarni P, Paranjape A, Pradhan R, Varghese R, Kasekar S, Nair V, Khanbande U. A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial. Int Immunopharmacol 2021;96:107743. [PMID: 33984718 DOI: 10.1016/j.intimp.2021.107743] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Al Ameer HH, AlKadhem SM, Busaleh F, AlKhwaitm S, Llaguno MBB. Multisystem Inflammatory Syndrome in Children Temporally Related to COVID-19: A Case Report From Saudi Arabia. Cureus 2020;12:e10589. [PMID: 33110725 DOI: 10.7759/cureus.10589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Fara A, Mitrev Z, Rosalia RA, Assas BM. Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biol. 2020;10:200160. [PMID: 32961074 DOI: 10.1098/rsob.200160] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
39 Manchanda K, Singh J, Bhagat R, Tiwana IK, Singh H. Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. Int J Risk Saf Med 2021;32:3-17. [PMID: 33386817 DOI: 10.3233/JRS-200060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhu X, Wang Y, Xiao Y, Gao Q, Gao L, Zhang W, Xin X, Chen K, Srivastava U, Ginjupalli VKM, Cupelli M, Lazzerini PE, Capecchi PL, Chen L, Boutjdir M. Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-04852-5] [Reference Citation Analysis]
41 Karmakar D, Lahiri B, Ranjan P, Chatterjee J, Lahiri P, Sengupta S. Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. Pathogens 2020;10:5. [PMID: 33374748 DOI: 10.3390/pathogens10010005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
42 Patel S, Saxena B, Mehta P. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19. Heliyon 2021;7:e06158. [PMID: 33553708 DOI: 10.1016/j.heliyon.2021.e06158] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
43 Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clin Immunol 2021;222:108615. [PMID: 33203513 DOI: 10.1016/j.clim.2020.108615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
44 Ozgür D, Karamese M, Medetalibeyoglu A, Alkan O, Senkal N, Tutuncu EE. High Levels of Circulating IL-6 and IL-8 Signature can Predict COVID-19 Severity. Jundishapur J Microbiol 2021;14. [DOI: 10.5812/jjm.119060] [Reference Citation Analysis]
45 Pinzon RT, Wijaya VO, Buana RB. Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J Infect Public Health 2021;14:1001-9. [PMID: 34153723 DOI: 10.1016/j.jiph.2021.06.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ghosh S, Das S, Mondal R, Abdullah S, Sultana S, Singh S, Sehgal A, Behl T. A review on the effect of COVID-19 in type 2 asthma and its management. Int Immunopharmacol 2021;91:107309. [PMID: 33385710 DOI: 10.1016/j.intimp.2020.107309] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 McGill AR, Kahlil R, Dutta R, Green R, Howell M, Mohapatra S, Mohapatra SS. SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. Infect Dis Rep 2021;13:102-25. [PMID: 33557330 DOI: 10.3390/idr13010013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
48 Kesmez Can F, Özkurt Z, Öztürk N, Sezen S. Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. Int J Clin Pract 2021;:e14970. [PMID: 34626520 DOI: 10.1111/ijcp.14970] [Reference Citation Analysis]
49 [DOI: 10.1101/2020.07.21.212639] [Cited by in Crossref: 31] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
50 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Londres HD, Armada JJ, Martínez AH, Abdo Cuza AA, Sánchez YH, Rodríguez AG, Figueroa SS, Llanez Gregorich EM, Torres Lahera ML, Peire FG, González TM, González YZ, Añé Kouri AL, Palomo AG, Concepción MT, Pérez LM, Luaces-Alvarez PL, Iglesias DE, Hernández DS, Suzarte MR, Ramos TC. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. Immunotherapy 2022. [PMID: 35306855 DOI: 10.2217/imt-2022-0027] [Reference Citation Analysis]
52 Benani A, Ben Mkaddem S. Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. Front Immunol 2020;11:1841. [PMID: 32793246 DOI: 10.3389/fimmu.2020.01841] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Bidram E, Esmaeili Y, Amini A, Sartorius R, Tay FR, Shariati L, Makvandi P. Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside. ACS Biomater Sci Eng 2021;7:2150-76. [PMID: 33979143 DOI: 10.1021/acsbiomaterials.1c00318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Peter AE, Sandeep BV, Rao BG, Kalpana VL. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. Front Pharmacol 2020;11:583777. [PMID: 33708109 DOI: 10.3389/fphar.2020.583777] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
55 Krejner-Bienias A, Grzela K, Grzela T. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End? Arch Immunol Ther Exp (Warsz) 2021;69:1. [PMID: 33527308 DOI: 10.1007/s00005-020-00602-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Sasidharan S, Singh V, Singh J, Madan GS, Dhillon HS, Dash PK, Shibu B, Dhillon GK. COVID-19 ARDS: A Multispecialty Assessment of Challenges in Care, Review of Research, and Recommendations. J Anaesthesiol Clin Pharmacol 2021;37:179-95. [PMID: 34349364 DOI: 10.4103/joacp.JOACP_14_21] [Reference Citation Analysis]
57 Trovato M, Sciacchitano S, Facciolà A, Valenti A, Visalli G, Di Pietro A. Interleukin‑6 signalling as a valuable cornerstone for molecular medicine (Review). Int J Mol Med 2021;47:107. [PMID: 33907833 DOI: 10.3892/ijmm.2021.4940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
58 Banji D, Alqahtani SS, Banji OJF, Machanchery S, Shoaib A. Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review. Saudi Pharm J 2021;29:213-22. [PMID: 33850422 DOI: 10.1016/j.jsps.2021.01.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Podlasin RB, Kowalska JD, Pihowicz A, Wojtycha-Kwaśnica B, Thompson M, Dyda T, Czeszko-Paprocka H, Horban A. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. Eur J Med Res 2020;25:37. [PMID: 32854774 DOI: 10.1186/s40001-020-00438-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Li S, Duan X, Li Y, Li M, Gao Y, Li T, Li S, Tan L, Shao T, Jeyarajan AJ, Chen L, Han M, Lin W, Li X. Differentially expressed immune response genes in COVID-19 patients based on disease severity. Aging (Albany NY) 2021;13:9265-76. [PMID: 33780352 DOI: 10.18632/aging.202877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Zafer MM, El-Mahallawy HA, Ashour HM. Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. Microorganisms 2021;9:159. [PMID: 33445583 DOI: 10.3390/microorganisms9010159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
62 Tuli HS, Sood S, Kaur J, Kumar P, Seth P, Punia S, Yadav P, Sharma AK, Aggarwal D, Sak K. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. 3 Biotech 2021;11:110. [PMID: 33552835 DOI: 10.1007/s13205-021-02644-8] [Reference Citation Analysis]
63 Alipoor SD, Mortaz E, Jamaati H, Tabarsi P, Bayram H, Varahram M, Adcock IM. COVID-19: Molecular and Cellular Response. Front Cell Infect Microbiol 2021;11:563085. [PMID: 33643932 DOI: 10.3389/fcimb.2021.563085] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
64 Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. Front Immunol 2020;11:583019. [PMID: 33178213 DOI: 10.3389/fimmu.2020.583019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
65 Zena-Huancas P, Leon-Jimenez F, Bryce-Alberti M, Portmann-Baracco A. Tocilizumab in COVID-19: enthusiasm vs. evidence. Lung India 2021;38:574-6. [PMID: 34747742 DOI: 10.4103/lungindia.lungindia_766_20] [Reference Citation Analysis]
66 Che Mohd Nassir CMN, Hashim S, Wong KK, Abdul Halim S, Idris NS, Jayabalan N, Guo D, Mustapha M. COVID-19 Infection and Circulating Microparticles-Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease. Mol Neurobiol 2021;58:4188-215. [PMID: 34176095 DOI: 10.1007/s12035-021-02457-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Chouw A, Milanda T, Sartika CR, Kirana MN, Halim D, Faried A. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. Regen Eng Transl Med 2021;:1-12. [PMID: 33723519 DOI: 10.1007/s40883-021-00202-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Kotru S, Klimuntowski M, Ridha H, Uddin Z, Askhar AA, Singh G, Howlader MMR. Electrochemical sensing: A prognostic tool in the fight against COVID-19. Trends Analyt Chem 2021;136:116198. [PMID: 33518850 DOI: 10.1016/j.trac.2021.116198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
69 Palacios Y, Chavez-galan L. Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative? Pharmaceuticals 2022;15:616. [DOI: 10.3390/ph15050616] [Reference Citation Analysis]